i-Stat's New Mainstream Partner: Abbott

i-Stat Corp., a leader in the point of care diagnostics business, is teaming up with Abbott Diagnostics to sell its hand-held POC devices to hospitals and clinics. The deal signals a change of heart on the part of both companies: Abbott has been sitting on the sidelines of the non-blood glucose POC market, watching it evolve, while i-Stat early on gained a reputation for trying to bypass laboratories in favor of selling directly to other hospital departments. Now, Abbott, which has a strong hold on clinical labs, will be taking over responsibility for all i-Stat sales, with the exception of territories carved out by another i-Stat partner, Hewlett-Packard.

The new strategic alliance between i-Stat Corp. and Abbott Laboratories Inc. signals something of an about-face for both companies [See Deal]. i-Stat initially steered clear of hospital central laboratories, pitching its innovative hand-held point-of-care (POC) blood analyzer to other hospital departments like critical care unit coordinators and hospital financial administrators, an approach that aroused considerable controversy. While the company has softened its stance in recent years, its deal with Abbott signifies a major effort on i-Stat's part to work through the central laboratory-where Abbott, after all, has a stronghold.

For Abbott, too, the relationship is a change in direction. While Abbott has been involved for several years in POC...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By 

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.

Rising leaders 2025: Aneesh Karatt-Vellatt On Maxion Therapeutics’ Antibody Revolution

 
• By 

Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.